Search

Your search keyword '"Lindman, Henrik"' showing total 656 results

Search Constraints

Start Over You searched for: Author "Lindman, Henrik" Remove constraint Author: "Lindman, Henrik"
656 results on '"Lindman, Henrik"'

Search Results

101. Metastatic or locally advanced breast cancer patients : towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumoursthe MACBETH project

102. Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer : results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?

103. Health-related quality of life in the Swedish PREDIX HER2 trial, evaluating docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer.

105. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial

106. Abstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)

108. Health-related quality of life in the Swedish PREDIX HER2 trial, evaluating docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer.

109. Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?

110. U-CAN : a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden.

112. Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer The SOLD Randomized Clinical Trial

113. Good adherence to adjuvant endocrine therapy in early breast cancer : a population-based study based on the Swedish prescribed Drug Register

114. Omitting radiotherapy in women >= 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe

116. A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1)

117. Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative

118. Abstract GS3-04: A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study)

119. U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden

120. Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

123. Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer

124. Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer

125. Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.

126. Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen

128. Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer : The Randomized Clinical FinXX Trial

129. Omitting radiotherapy in women >= 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe

130. Good manufacturing practice production of [68Ga]Ga-ABY-025 for HER2 specific breast cancer imaging

131. U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden

132. Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer

133. Long-term safety and survival outcomes from the Scandinavian Breast Group 2004–1 (SBG 2004-1) randomized trial of tailored dose adjuvant chemotherapy for early breast cancer.

136. Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT

137. Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule Ga-68-ABY-025 in Breast Cancer Patients

141. Abstract CT020: MERIT: introducing individualized cancer vaccines for the treatment of TNBC - a phase I trial

142. Adjuvant capesitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial.

143. Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients

144. Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT

145. Mutanome Engineered RNA Immunotherapy (MERIT)

146. Is pathologic complete response (pCR) a valid marker of outcome even in large breast cancer? : Clinical results from a neoadjuvant trial using a combination of epirubicin, docetaxel and bevacizumab (PROMIX)

147. Lymphoedema and health-related quality of life by early treatment in long-term survivors of breast cancer. A comparative retrospective study up to 15 years after diagnosis

148. Non-invasive determination of HER2-expression in metastatic breast cancer by using Ga-68-ABY025 PET/CT.

149. Accuracy of [Ga-68]ABY-025 PET/CT for determination of HER2-expression in metastatic breast cancer

Catalog

Books, media, physical & digital resources